Meta Information
ID:omega-3-epa-dha
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-10T18:48:18.503789Z
Model
Gemini 3.1 Pro (High)
Interactions
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Significantly increases the risk of serious bleeding by compounding the blood-thinning effects of these medications.
Actionable advice:
Requires close medical supervision.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
COUMADIN can cause bleeding which can be serious and sometimes lead to death.
Label source:
Action type:
informational_none
Target id:
/intervention/icosapent-ethyl
Target name:
Icosapent Ethyl
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
This is a prescription omega-3; taking more can increase risks like bleeding or atrial fibrillation.
Actionable advice:
These should not be combined without medical direction.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
(5.1)
Indications and Usage (1) 12/2019 Potential for Allergic Reactions in Patients with Fish Allergy: VASCEPA
Warnings and Precautions, Atrial Fibrillation/Flutter (5.1) 12/2019 contains ethyl esters of the omega-3 fatty acid, eicosapentaenoic acid (EPA),
Warnings and Precautions, Bleeding (5.3) 12/2019 obtained from the oil of fish.
Label source:
Action type:
avoid
Target id:
/class/nsaids
Target name:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Increases the risk of gastrointestinal bleeding and bruising due to combined antiplatelet (blood-thinning) effects.
Actionable advice:
The combination should be used with caution.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The concurrent use of aspirin and an
NSAID, such as celecoxib, increases the risk of serious gastrointestinal (GI) events [see
Warnings and Precautions (5.2)].
Label source:
Action type:
informational_none
Target id:
/class/fibrates
Target name:
Fibrates
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both significantly lower triglycerides; their combined use can be highly effective for managing hypertriglyceridemia.
Actionable advice:
Requires medical supervision and monitoring.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The current approach to the management of hypertriglyceridemia is based on lifestyle changes and, usually, drug combinations (statin and fibrate and/or omega-3 fatty acids or niacin).
Label source:
PubMed: Treatment of hypertriglyceridemia: a review of current options. (PMID 26680666)
Action type:
monitor
Target id:
/class/bile-acid-sequestrants
Target name:
Bile Acid Sequestrants
Severity:
moderate
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
4
Hours after target:
4
Description:
May bind to omega-3s in the gut, reducing their absorption and overall effectiveness.
Actionable advice:
Doses should be separated by at least 4 hours.
Validation status:
validated_via_clinical_guidance
Evidence tier:
tier_b
Evidence basis:
clinical_guidance_verbatim
Evidence anchors:
Exact phrase from label:
Bile acid sequestrants have been reported to impair the absorption of numerous nutrients and fat-soluble vitamins, including calcium, folate, iron, vitamin A, vitamin B12, and vitamin E
Label source:
Clinical guidance: EBSCO Research Starters — Bile acid sequestrant drugs (drug interactions)
Action type:
separate
Target id:
/class/statins
Target name:
Statins
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Often used together to improve the overall lipid profile, lowering both triglycerides and LDL cholesterol.
Actionable advice:
The lipid panel should be monitored as directed.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
After fish oil treatment, triglyceride levels decreased by 0.28 +/- 0.08 mmol/L more than control (P = 0.01), and very-low-density lipoprotein cholesterol levels decreased by 0.13 +/- 0.04 mmol/L more than control (P = 0.01).
Label source:
PubMed: Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. (PMID 7486485)
Action type:
monitor
Target id:
/class/herbal-anticoagulants
Target name:
Herbal Anticoagulants/Antiplatelets
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining with other herbal blood-thinners increases the risk of bruising or more serious bleeding events.
Actionable advice:
Multiple blood-thinning supplements are best not combined.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
These supplements can potentially alter bleeding and coagulation during surgery and when used concomitantly with anticoagulants
Label source:
Primary literature: https://pmc.ncbi.nlm.nih.gov/articles/PMC9586694/
Action type:
avoid
Target id:
/intervention/ezetimibe
Target name:
Ezetimibe
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Works with ezetimibe to further lower triglyceride levels, which is often a therapeutic goal.
Actionable advice:
The lipid panel should be monitored as directed.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
If cholelithiasis is suspected in a patient receiving ezetimibe and fenofibrate, gallbladder studies are indicated and alternative lipid- lowering therapy should be considered.
Label source:
Action type:
monitor
Target id:
/intervention/vitamin-e
Target name:
Vitamin E
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both have mild blood-thinning properties, which could slightly increase the risk of bruising or bleeding.
Actionable advice:
Caution is warranted with high doses.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Omega-3 fatty acids, berberine, garlic, and nattokinase exert favorable metabolic and vascular effects, yet their clinical efficacy depends on formulation, dosage, and patient characteristics and may be limited by bleeding risk or drug interactions. Antioxidant agents such as vitamin C, vitamin E, resveratrol, astaxanthin, and coenzyme Q provide additional vascular protection but can interfere with hemostasis, metabolism, or redox-sensitive pathways.
Label source:
PubMed: International journal of molecular sciences (2025)
Source url:
Exact phrase from label:
omega 3-fatty acids in fish oil, ajoene in garlic, ginger, ginko, and vitamin E (antiplatelet properties)
Label source:
PubMed: Methods in molecular biology (Clifton, N.J.) (2010)
Source url:
Exact phrase from label:
This review considers the potential of certain dietary supplements, including garlic, Ginkgo biloba, ginger, ginseng, fish oil, and vitamin E, to interfere with hemostasis.
Label source:
PubMed: Nutrition reviews (2012)
Action type:
informational_none
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
May enhance the blood pressure-lowering effects of these medications, potentially causing dizziness or lightheadedness.
Actionable advice:
It is a good idea to check blood pressure regularly.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Nutrigenetic interactions, particularly the effects of folate and riboflavin on methylenetetrahydrofolate reductase polymorphisms, exhibit blood pressure-lowering and stroke-preventive advantages.
Label source:
PubMed: B vitamins and cardiovascular health: mechanisms, clinical evidence, and precision prevention strategies. (PMID 42067935)
Action type:
monitor
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
High doses may slightly affect blood sugar levels, requiring monitoring in those on diabetes medication.
Actionable advice:
It is a good idea to check blood glucose levels.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 10/2023
12.1 Mechanism of Action Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose.
Label source:
Action type:
monitor